Life Science & Biotech

Packaging manufacturer plans to expand, add 80 jobs

August 2, 2011
Indianapolis-based DGP Intelsius LLC, a manufacturer and distributor of temperature-controlled packaging, announced on Tuesday morning that it plans to add 80 jobs by 2014 as part of an $870,000 expansion.
More

More life sciences firms opt to launch products in EuropeRestricted Content

July 30, 2011
Maria LaMagna
The U.S. Food and Drug Administration's growing reputation for unpredictability is spurring some Indianapolis companies to join counterparts elsewhere and introduce products in Europe. The upshot is that some Americans may never benefit from innovations occurring in their backyards.
More

Indiana life sciences leaders look toward the futureRestricted Content

July 30, 2011
Chris O'Malley
Former Eli Lilly and Co. vice president Richard Dimarchi, BioCrossroads President David Johnson, angel investor Oscar Moralez and Purdue University Senior Vice President Alan Rebar discuss issues ranging from the depth of the life sciences industry in Indiana to venture capital and Purdue's Discovery Park.
More

Eli Lilly's Elanco unit blossoming at just the right timeRestricted Content

July 30, 2011
Greg Andrews
An investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass $3 billion by 2018.
More

Angel investment firm adds 3rd chapter for life sciences

July 27, 2011
Chris O'Malley
Moralez_watch_videoStepStone Business Partners has added a chapter in biotech hotbed Warsaw as part of what it hopes will eventually become a statewide network.
More

Dow AgroSciences reports record sales, higher earnings

July 27, 2011
Second-quarter revenue for the Indianapolis-based company increased 18 percent, to $1.5 billion. The company attributed the gain to higher prices and stronger demand for its products.
More

Tech district could boost Indianapolis' convention businessRestricted Content

July 23, 2011
Scott Olson
The Indianapolis Convention & Visitors Association plans to attract more life sciences conferences.
More

Pfizer won’t break up animal unit for potential Lilly bid

July 21, 2011
Bloomberg News
Pfizer Inc., the world’s biggest drugmaker, said it isn’t interested in breaking up its animal health unit after Indianapolis-based Eli Lilly and Co. expressed interest in buying some of its products.
More

Lilly loses bid to end revived Zyprexa U.K. patent case

July 5, 2011
Bloomberg News
The High Court in London on Tuesday denied Lilly’s request for a judgment without trial against Neopharma Ltd., the closely held company that has European marketing rights for the generic version of the drug known chemically as olanzapine.
More

Timing good for 2-in-1 biotech drugs

July 5, 2011
J.K. Wall
Eli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the world’s most successful biotech medicines, which are about to see their patents expire.
More

Lilly plans more investment in two-in-one drugs

June 28, 2011
J.K. Wall
Indianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act like two medicines in one. Lilly plans to add more scientists to back the effort.
More

Lilly CEO: Immigration, tax laws slow innovation

June 23, 2011
Bloomberg News
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. CEO John Lechleiter plans to tell a technology conference Thursday.
More

2010 was great for Indiana's 100 largest companiesRestricted Content

June 18, 2011
Norm Heikens
Despite enjoying rising revenues and profits, companies haven't followed with big increases in job numbers.
More

City leaders look to 16th Street as future tech hub

June 16, 2011
Francesca Jarosz
Officials on Thursday shared details of a long-term plan to redevelop an industrial stretch northwest of downtown with the goal of attracting hundreds of residents and dozens of high-tech companies to the area.
More

Q&A

June 13, 2011
J.K. Wall
Vi Shukla is a scientific leader at Indianapolis-based Dow AgroSciences LLC, focused on its Exzact Precision Technology tools for genetic engineering of plants and crops. Dow Agro used the technology in its own crop seed products, and has also been licensing for use in tomatos and trees.
More

Anson Group CEO thrives on helping clients work with FDARestricted Content

June 11, 2011
Ann Finch
Colleen Hittle became CEO and sole owner of the Indianapolis-based pharmaceutical and medical device consulting firm in April.
More

City to roll out plan for 16th Street tech corridor

June 10, 2011
Francesca Jarosz
The city of Indianapolis plans to announce a major initiative to turn a stretch of 16th Street northwest of downtown into a hub for biotechnology and other high-tech companies.
More

Roche wins as high court limits university patent rights

June 6, 2011
Bloomberg News
Monday's Supreme Court decision is a victory for companies that collaborate with universities in research. Indianapolis-based Eli Lilly and Co. was among the companies that supported Roche.
More

Life sciences logistics firm opens new tissue storage facility

May 27, 2011
J.K. Wall
BioStorage Technologies' $4.6 million facility, located near the Indianapolis International Airport, will be used to prepare, store and transport tissue and blood samples.
More

Brain barrier breached in push to deliver Alzheimer's drug

May 25, 2011
Scientists with Roche Holding AG, the parent company of Indianapolis-based Roche Diagnostics Corp., may have found a way to overcome a blood barrier that keeps drugs from directly entering the brain, potentially opening new pathways to attack Alzheimer’s disease.
More

Lilly licenses Xigris rights to new biotech firm

May 23, 2011
J.K. Wall
Eli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created local biotech company called BioCritica that will seek to reinvigorate sales of the medication.
More

Zimmer faces new threat to dominance

May 16, 2011
J.K. Wall
Warsaw-based Zimmer Holdings Inc. has enjoyed eight years as the giant in the industry of selling knee- and hip-replacement implants to hospitals. But now it faces a challenge from Johnson & Johnson.
More

BISHOP: Warsaw's orthopedics whizzes will master biologicsRestricted Content

May 14, 2011
Industry cluster in northern Indiana has adapted to every other change in health care, and will absorb tissue regeneration, too.
More

Endocyte's potential enthralls investorsRestricted Content

May 7, 2011
Chris O'Malley
Shares of Endocyte Inc. have doubled since the company’s initial public offering in February—even though the common wisdom is it won’t see sales from its first cancer drug until 2014.
More

Indianapolis bio sector hopeful as venture firms cash outRestricted Content

April 30, 2011
Chris O'Malley
Profits flowing from earlier investments could mean more available capital, but firms continue to be selective in placing their bets.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. The $104K to CRC would go toward debts service on $486M of existing debt they already have from other things outside this project. Keystone buys the bonds for 3.8M from CRC, and CRC in turn pays for the parking and site work, and some time later CRC buys them back (with interest) from the projected annual property tax revenue from the entire TIF district (est. $415K / yr. from just this property, plus more from all the other property in the TIF district), which in theory would be about a 10-year term, give-or-take. CRC is basically betting on the future, that property values will increase, driving up the tax revenue to the limit of the annual increase cap on commercial property (I think that's 3%). It should be noted that Keystone can't print money (unlike the Federal Treasury) so commercial property tax can only come from consumers, in this case the apartment renters and consumers of the goods and services offered by the ground floor retailers, and employees in the form of lower non-mandatory compensation items, such as bonuses, benefits, 401K match, etc.

  2. $3B would hurt Lilly's bottom line if there were no insurance or Indemnity Agreement, but there is no way that large an award will be upheld on appeal. What's surprising is that the trial judge refused to reduce it. She must have thought there was evidence of a flagrant, unconscionable coverup and wanted to send a message.

  3. As a self-employed individual, I always saw outrageous price increases every year in a health insurance plan with preexisting condition costs -- something most employed groups never had to worry about. With spouse, I saw ALL Indiana "free market answer" plans' premiums raise 25%-45% each year.

  4. It's not who you chose to build it's how they build it. Architects and engineers decide how and what to use to build. builders just do the work. Architects & engineers still think the tarp over the escalators out at airport will hold for third time when it snows, ice storms.

  5. http://www.abcactionnews.com/news/duke-energy-customers-angry-about-money-for-nothing

ADVERTISEMENT